

18/11/24

Dear Colleague,

**Updates to Immunology Lymphocyte Subset Extended Panels**

We are pleased to inform you of some important updates to the Immunology laboratory lymphocyte subset extended marker panels. We have recently reviewed the lymphocyte subset extended panels and have updated them in line with clinical/best practice guidelines and following discussion with our service users. The planned go live date for this change is Monday 27th January 2025.

**The new extended panels are detailed below:**

Extended Panels	Key Markers	Purpose/Indication
Lymphocyte subsets (Child Panel)	HLA-DR/CD25 DNT* cells CD11a/CD18 MHC Class I CD45RA/RO/27	Paediatric samples – all new requests for investigation of possible immune deficiency (i.e. unless HIV, biological therapy etc.) May be requested directly by Paediatric Immunologists
Lymphocyte subsets (Paediatric BMT panel)	HLA-DR DNT* cells AB**/GD*** TCR CD45RA/RO/27	Follow up of paediatric patients who have undergone HSCT for PID
Lymphocyte Subsets (Adult Extended PID Panel)	HLA-DR/CD25 DNT* cells CD45RA/RO/27 CD11a/CD18 CD2/CD7 CD5/CD19 Kappa/Lambda	Adult samples – all new requests for investigation of possible immune deficiency. May be requested directly by Immunologists
Lymphocyte Subsets (Adult Panel)	HLA-DR/CD25 DNT* cells CD2/CD7 CD5/CD19 Kappa/Lambda	Adult samples – limited markers
Lymphocyte subsets (Gamma/delta)	GD*** TCR	Added if T sum suggests possible presence of gamma/delta T cells. Routinely added in HIV+/post HSCT patients with T sum >10% if not done in past year. Routinely added for other patients if T sum is >5% May be requested directly by Immunologists

\*DNT = Double negative T cells    \*\* AB = alpha beta T cells    \*\*\* GD = gamma delta T cells

‡ Additional CD markers are used in the gating of these panels – for further information contact laboratory.

All the above results will be reported with the following interpretative guide:

- DNT cells (CD3+AB+CD4-CD8-) reported as % of CD3+AB+ T cells
- CD4+27+RA+(naive) & CD4+27+RO+(memory) reported as % of CD4+ T cells
- CD8+27+RA+(naive) & CD8+27+RO+(memory) reported as % of CD8+ T cells
- Kappa+ & Lambda+ reported as % of CD19+ B cells
- CD3+gamma/delta+ T cells reported as % of CD3+ T cells
- All other populations reported as a % of total lymphocytes

**Current Basic Panel (lymphocyte subsets) – Remains Unchanged**

Basic Panel	Markers	Purpose/Indication
Lymphocyte subsets (T, B and NK cells)	CD3 CD4 CD8 CD19 CD16/56	New and follow up samples for <ul style="list-style-type: none"><li>• HIV positive patients</li><li>• Biological / similar therapies e.g. Rituximab, ATG, CAR-T therapy</li><li>• Post HSCT monitoring</li><li>• PID patients</li></ul>

**Requesting Lymphocyte Subset Extended Panels**

The requesting process will remain the same therefore no changes are required for service users. Sample type and volume remains the same and the turnaround time for these tests will be unaffected (7 days). All information relating to sample requirements can be found in our handbook which can be accessed online ([www.nhsggc.scot/inilab](http://www.nhsggc.scot/inilab))

**Results for Lymphocyte Subset Extended Panels**

The format of the results will change with the new extended panels. For internal GGC users, you will continue to receive results via Trakcare and Clinical portal which will be updated with the new panels, therefore there is no action required.

For external labs, if you input results into your local LIMS please get in touch and we can provide the new format for results. If you currently scan reports to your local LIMS there should be no requirement to make any changes.

**Cost per test**

For external Health Boards, the cost per panel will change when we go live and details of this will be communicated separately.

Please do not hesitate to get in touch if you have any questions regarding this update.

Yours sincerely,



Lauren Hennessy  
Consultant Clinical Scientist  
Clinical Lead for Immunology & Neuroimmunology Laboratory